Read More

EyePoint Pharmaceuticals Announces Two Presentations Of Topline Data With Additional Subgroup Analyses From The Phase 2 DAVIO 2 Clinical Trial Of EYP-1901 For The Treatment Of Wet Age-Related Macular Degeneration

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were

EYPT